ETF Holdings Breakdown of TSHA

Stock Name	Taysha Gene Therapies Inc
Ticker	TSHA(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US8776191061

News associated with TSHA

Marshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Marshall Wace LLP reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 71.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 138,111 shares of the company’s stock after selling 347,915 shares during the period. Marshall Wace LLP’s holdings in Taysha Gene Therapies were worth $239,000 at the end of […] - 2025-05-06 07:44:54
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Analysts: Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has been given a consensus recommendation of “Buy” by the eight analysts that are covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in […] - 2025-05-05 07:28:56
Renaissance Technologies LLC Makes New $1.52 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Renaissance Technologies LLC purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 878,448 shares of the company’s stock, valued at approximately $1,520,000. Renaissance Technologies LLC owned approximately 0.43% of Taysha Gene […] - 2025-04-28 08:05:14
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages: Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on […] - 2025-04-08 05:33:03
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages: Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued a report on […] - 2025-02-17 06:29:09

TSHA institutional holdings

The following institutional investment holdings of TSHA have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 91,515 USD 192,182 9.5%

2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 91,515 USD 192,182 9.5%

Total = 183,030 USD 384,364
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	91,515	USD 192,182 9.5%
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	91,515	USD 192,182 9.5%
Total =	183,030	USD 384,364

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.